Influence of central administration ATP-dependent K+ channel on morphine state-dependent memory of passive avoidance.
Pre-training injection of a moderate dose of morphine (5-10 mg/kg) in a step-down passive avoidance task induced state-dependent learning with impaired memory retrieval on the test day. The impairment of memory was restored after the pre-test administration of the same dose of the drug. We have studied the effect of intracerebroventricular administration of naloxone and K(ATP) channel modulators (glibenclamide and diazoxide) on the test day on restoration of memory by morphine in mice. The effect of scopolamine on restoration of memory on the test-day by glibenclamide was studied as well. Naloxone pretreatment (0.006, 0.025 and 0.1 microg/mouse) reversed the effect of pre-test morphine administration. The K(ATP) channel blocker, glibenclamide (0.1, 0.5 and 1 microg/mouse), showed effects similar to those of pre-test administration of morphine. Glibenclamide tended to potentiate the morphine response. Scopolamine (0.15 and 0.30 microg/mouse) prevented the effect of glibenclamide on the restoration of memory. The pre-test administration of different doses of diazoxide (1.7, 5 and 15 microg/mouse), a K(ATP) channel opener, showed no effect on restoration of memory when used alone but decreased morphine state-dependence. Diazoxide blocked the effects of glibenclamide on memory restoration. It is concluded that K(ATP) channel modulators may be involved, at least in part, in morphine state dependence through a cholinergic system mechanism.
Zarrindast
Mohammad R
MR
Department of Pharmacology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. zarinmr@ams.ac.ir
Jafari
Mohammad R
MR
Ahmadi
Shamseddin
S
Djahanguiri
Bijan
B
D018528:ATP-Binding Cassette Transporters; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects*; D003981:Diazoxide / Q000494:pharmacology; D005905:Glyburide / Q000494:pharmacology; D007276:Injections, Intraventricular; D054086:KATP Channels; D008297:Male; D008568:Memory / Q000187:drug effects*; D051379:Mice; D009020:Morphine / Q000494:pharmacology*; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009294:Narcotics / Q000494:pharmacology*; D010275:Parasympathetic Nervous System / Q000187:drug effects; D026902:Potassium Channel Blockers / Q000494:pharmacology; D015221:Potassium Channels / Q000819:agonists / Q000187:drug effects*; D024661:Potassium Channels, Inwardly Rectifying; D012601:Scopolamine / Q000494:pharmacology
D018528:ATP-Binding Cassette Transporters; D054086:KATP Channels; D018727:Muscarinic Antagonists; D009292:Narcotic Antagonists; D009294:Narcotics; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024661:Potassium Channels, Inwardly Rectifying; C092520:uK-ATP-1 potassium channel; D009270:Naloxone; D009020:Morphine; D012601:Scopolamine; D003981:Diazoxide; D005905:Glyburide